Madrigal Pharma (MDGL) Tops Q2 EPS by 38c

Madrigal Pharma (NASDAQ: MDGL) reported Q2 EPS of ($7.10), $0.38 better than the analyst estimate of ($7.48). Revenue for the quarter came in at $14.6 million versus the consensus estimate of $4.25 million.

For earnings history and earnings-related data on Madrigal Pharma (MDGL) click here.

You May Also Be Interested In

• Trump on Iran: we're trying to work out a deal that's fair
• Popular stocks with increasing option volume: SPCX MU INTC NFLX PLTR SOFI MSTR AMC IBM SMCI HOOD
• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI